JP4502503B2 - 増殖性の疾患を処置するためのベンゾシクロヘプタピリジン化合物および抗腫瘍剤の組合せ - Google Patents

増殖性の疾患を処置するためのベンゾシクロヘプタピリジン化合物および抗腫瘍剤の組合せ Download PDF

Info

Publication number
JP4502503B2
JP4502503B2 JP2000525105A JP2000525105A JP4502503B2 JP 4502503 B2 JP4502503 B2 JP 4502503B2 JP 2000525105 A JP2000525105 A JP 2000525105A JP 2000525105 A JP2000525105 A JP 2000525105A JP 4502503 B2 JP4502503 B2 JP 4502503B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
substituted
embedded image
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000525105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001526224A5 (OSRAM
JP2001526224A (ja
Inventor
ウォルター アール． ビショップ，
ジョセフ ジェイ． カチノ，
ロナルド ジェイ． ドール，
アシット ガングリー，
ビヨール ギリジャバラバン，
ポール カーシュメイヤー，
ミン リュ，
ロレッタ エル． ニールセン，
デイビッド エル． カトラー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4502503(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2001526224A publication Critical patent/JP2001526224A/ja
Publication of JP2001526224A5 publication Critical patent/JP2001526224A5/ja
Application granted granted Critical
Publication of JP4502503B2 publication Critical patent/JP4502503B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2000525105A 1997-12-22 1998-12-21 増殖性の疾患を処置するためのベンゾシクロヘプタピリジン化合物および抗腫瘍剤の組合せ Expired - Fee Related JP4502503B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US08/996,027 1997-12-22
US14352998A 1998-08-28 1998-08-28
US09/143,529 1998-08-28
US18196998A 1998-10-29 1998-10-29
US09/181,969 1998-10-29
PCT/US1998/026224 WO1999032114A1 (en) 1997-12-22 1998-12-21 Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases

Publications (3)

Publication Number Publication Date
JP2001526224A JP2001526224A (ja) 2001-12-18
JP2001526224A5 JP2001526224A5 (OSRAM) 2006-02-09
JP4502503B2 true JP4502503B2 (ja) 2010-07-14

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000525105A Expired - Fee Related JP4502503B2 (ja) 1997-12-22 1998-12-21 増殖性の疾患を処置するためのベンゾシクロヘプタピリジン化合物および抗腫瘍剤の組合せ

Country Status (25)

Country Link
EP (1) EP1041985B1 (OSRAM)
JP (1) JP4502503B2 (OSRAM)
KR (1) KR100700907B1 (OSRAM)
CN (1) CN1129431C (OSRAM)
AR (1) AR017440A1 (OSRAM)
AT (1) ATE317697T1 (OSRAM)
AU (1) AU756762B2 (OSRAM)
BR (1) BR9814419A (OSRAM)
CA (1) CA2315693C (OSRAM)
CL (1) CL2007001889A1 (OSRAM)
CO (1) CO5080764A1 (OSRAM)
CZ (1) CZ298511B6 (OSRAM)
DE (1) DE69833509T2 (OSRAM)
DK (1) DK1041985T3 (OSRAM)
ES (1) ES2255196T3 (OSRAM)
HU (1) HUP0102473A3 (OSRAM)
IL (1) IL136462A0 (OSRAM)
MY (1) MY137303A (OSRAM)
NO (1) NO326832B1 (OSRAM)
NZ (1) NZ504928A (OSRAM)
PE (1) PE20000042A1 (OSRAM)
PT (1) PT1041985E (OSRAM)
SK (1) SK285584B6 (OSRAM)
TW (1) TW581763B (OSRAM)
WO (1) WO1999032114A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
AU1400401A (en) * 1999-11-09 2001-06-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
EP1261348A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
CA2397657A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations with platinum compounds
CA2397253A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
CA2397475A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
AU2001239275A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
WO2001064195A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
ES2318000T3 (es) * 2001-02-15 2009-05-01 Janssen Pharmaceutica Nv Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos.
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
WO1997005902A1 (fr) * 1995-08-09 1997-02-20 Banyu Pharmaceutical Co., Ltd. Composition medicinale
CZ292791B6 (cs) * 1995-12-22 2003-12-17 Schering Corporation Tricyklické amidy, které se používají pro inhibici G-proteinové funkce a k léčení proliferativních onemocnění
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
AU715604B2 (en) * 1996-04-03 2000-02-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000508661A (ja) * 1996-04-15 2000-07-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 放射線および化学療法に対する細胞の感作
WO1997038664A2 (en) * 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
EP0934270A1 (en) * 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
US6337992B1 (en) * 1997-01-29 2002-01-08 Philips Medical Systems Technologies Ltd. Predictive bolus tracking
HUP0004326A3 (en) * 1997-02-18 2003-07-28 Canji Inc San Diego Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Also Published As

Publication number Publication date
MY137303A (en) 2009-01-30
KR100700907B1 (ko) 2007-03-29
TW581763B (en) 2004-04-01
NO20003229L (no) 2000-08-22
CO5080764A1 (es) 2001-09-25
DK1041985T3 (da) 2006-06-19
WO1999032114A1 (en) 1999-07-01
AR017440A1 (es) 2001-09-05
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
EP1041985B1 (en) 2006-02-15
DE69833509D1 (de) 2006-04-20
PE20000042A1 (es) 2000-02-17
NO20003229D0 (no) 2000-06-21
CN1284875A (zh) 2001-02-21
CZ298511B6 (cs) 2007-10-24
JP2001526224A (ja) 2001-12-18
IL136462A0 (en) 2001-06-14
AU1907299A (en) 1999-07-12
DE69833509T2 (de) 2006-10-26
CA2315693C (en) 2010-11-30
CL2007001889A1 (es) 2008-01-11
NZ504928A (en) 2004-12-24
SK285584B6 (sk) 2007-04-05
AU756762B2 (en) 2003-01-23
ATE317697T1 (de) 2006-03-15
CN1129431C (zh) 2003-12-03
NO326832B1 (no) 2009-02-23
PT1041985E (pt) 2006-07-31
HUP0102473A2 (hu) 2002-01-28
CZ20002236A3 (cs) 2001-04-11
KR20010033452A (ko) 2001-04-25
EP1041985A1 (en) 2000-10-11
ES2255196T3 (es) 2006-06-16
HUP0102473A3 (en) 2003-07-28
SK8982000A3 (en) 2001-04-09

Similar Documents

Publication Publication Date Title
US6333333B1 (en) Methods for treating proliferative diseases
ES2275505T3 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores.
EP1041985B1 (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
US10993953B2 (en) Method for treating cancer using chemokine antagonists
US20040072760A1 (en) Synergistic methods and compositions for treating cancer
HUP0301690A2 (hu) Szinergikus eljárások és készítmények rák kezelésére
US6777415B2 (en) Methods of inducing cancer cell death and tumor regression
AU2002211862A1 (en) Methods of inducing cancer cell death and tumor regression
CA2672650C (en) Compositions and methods for the treatment of cancer
TW202131917A (zh) 併用醫藥
JP2005504065A (ja) 癌治療のための組成物および方法
ES3038469T3 (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy
MXPA00006257A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
TW202606693A (zh) 藥物組合產品及其用途
TWI528960B (zh) 用於治療增生性疾病的醫藥組合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090508

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090609

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100316

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100415

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100420

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130430

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140430

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

LAPS Cancellation because of no payment of annual fees